Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.

In the primary analysis of the EXCEED study, secukinumab narrowly missed statistical significance for the primary endpoint of ACR 20 response at week 52; 67·4% with secukinumab vs. 61·5% with adalimumab ( P = 0·071). 17 In this prespecified analysis of patients with PsA who had moderate‐to‐severe psoriasis, secukinumab showed consistent improvements with respect to efficacy compared with adalimumab for musculoskeletal outcomes (ACR 20/50 responses, resolution of enthesitis and resolution of dactylitis), composite indices targeting remission or LDA, and physical function outcomes at week 52.

also in 227 other papers